

Provectus Pharmaceuticals, Inc. (PVCT.OB)

INVITES YOU to an UPDATE on

PV-10 for Metastatic Melanoma that is presented at ASCO,

WITH GUEST SPEAKERS

DR. SANJIV AGARWALA

Chief of Oncology and Hematology

**St. Luke's Hospital and Health Network, Bethlehem, PA, and one of
the lead investigators of the PV-10 Phase 2 trial**

AND

ERIC WACHTER, PH.D., EVP

Provectus Pharmaceuticals, Inc

AT

THE HYATT REGENCY CHICAGO

(Located at 151 East Wacker Drive, Chicago, IL 60601)

ON JUNE 7TH, 2010

AT 8:00 AM – 9:30 AM

Breakfast will be served

TOPIC: *CHEMOABLATION IN MELANOMA – THE PROVECTUS PHARMACEUTICAL STORY AND PROGRESS WITH PV-10*, based on a compound with an established safety profile, selective Mechanism of Action and FDA Orphan Drug designation. PV-10 is a proprietary, injectable formulation of Rose Bengal, for treatment of solid tumor cancers. PH-10, a less concentrated topical form of the drug is being developed for dermatological applications. Rose Bengal has been used for nearly 50 years by ophthalmologists and optometrists to assess damage to the eye, and has also been used to detect liver ailments. Its unique properties offer several distinct advantages in treating a broad range of solid tumor cancers and dermatological diseases.

RSVP: MARLON NURSE at 212-564-4700 or marlon@plrinvest.com by June 2nd, 2010